A Phase 3 interventional study of 75 mg linzagolix tablet and 200 mg linzagolix tablet in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Terminated at 112 sites in 3 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.
Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2019, is one of 5 in phase 3, and was the 6th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2019.
This study's enrollment of 85 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 100 across the 9 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 9 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing linzagolix in Endometriosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07015268Phase 3Kissei Pharmaceutical Co., Ltd.A Clinical Study of KLH-2109 in Patients With Endometriosis | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing linzagolix in Endometriosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).
This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the management of moderate to severe EAP in 450 women.
Eligible subjects who have completed the 6-month treatment period may enter a separate extension study for 6 additional months of active treatment (no placebo control). Subjects who do not continue in the extension study will enter a 6 month treatment-free follow-up phase.
Key Inclusion Criteria:
The subject must have:
Key Exclusion Criteria:
The subject will be excluded if she:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule
Drug: 200 mg linzagolix tablet · Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg) · Drug: Placebo tablet to match 75 mg linzagolix tablet
Drug: Placebo tablet to match 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule
For oral administration once daily
For oral administration once daily
Drug page: Estradiol
For oral administration once daily
For oral administration once daily
For oral administration once daily
For oral administration once daily
Dysmenorrhea
Change at Month 3 from baseline in the mean daily assessment of dysmenorrhea (DYS) measured on a 4-point Verbal Rating Scale (VRS) using an electronicdiary * The 4-point VRS scale for DYS ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the pain of DYS.
Time frame: Baseline to Month 3
Non-menstrual Pelvic Pain
Change at Month 3 from baseline in the mean daily assessment of non-menstrual pelvic pain (NMPP) measured on a 4-point Verbal Rating Scale (VRS) using anelectronic diary * The 4-point VRS scale for NMPP ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the NMPP.
Time frame: Baseline to Month 3
Of the 492 subjects screened, 85 were randomized. Between randomization and Day 1 (i.e., first day of dosing), 1 subject in the placebo group discontinued due to protocol deviation. Thus, 84 randomized subjects were treated and comprised the Safety Analysis Set.
| Milestone | LGX 75 mg | LGX 200 mg+ABT | Placebo |
|---|---|---|---|
| Started | 28 | 29 | 27 |
| Completed | 13 | 10 | 8 |
| Not completed | 15 | 19 | 19 |
| Withdrew: Adverse event | 1 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 5 | 5 |
| Withdrew: Study termination | 10 | 10 | 10 |
| Withdrew: Discontinuation after moving to follow-up period [study termination per sponsor] | 1 | 0 | 0 |
| Withdrew: Discontinuation after moving to follow-up period [subject's request (family issue)] | 0 | 1 | 0 |
Change at Month 3 from baseline in the mean daily assessment of dysmenorrhea (DYS) measured on a 4-point Verbal Rating Scale (VRS) using an electronicdiary * The 4-point VRS scale for DYS ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the pain of DYS.
| score on a scale | LGX 75 mg | LGX 200 mg+ABT | Placebo |
|---|---|---|---|
| Dysmenorrhea | -0.5 ± 0.5 | 0.0 ± 0.0 | 0.5 ± 0.5 |
Change at Month 3 from baseline in the mean daily assessment of non-menstrual pelvic pain (NMPP) measured on a 4-point Verbal Rating Scale (VRS) using anelectronic diary * The 4-point VRS scale for NMPP ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the NMPP.
| score on a scale | LGX 75 mg | LGX 200 mg+ABT | Placebo |
|---|---|---|---|
| Non-menstrual Pelvic Pain | -1.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Collected over - Treatment Period: 6 months (Day 1 to Month 6) - Follow-up Period: 6 months (Month 6 to Month 6 FU). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LGX 75 mg | 0/28 (0%) | 0/28 (0%) | 10/28 (35.7%) |
| LGX 200 mg+ABT | 0/29 (0%) | 0/29 (0%) | 16/29 (55.2%) |
| Placebo | 0/27 (0%) | 0/27 (0%) | 12/27 (44.4%) |
| Event | LGX 75 mg | LGX 200 mg+ABT | Placebo |
|---|---|---|---|
| COVID-19Infections and infestations | 0/28 | 1/29 | 3/27 |
| NauseaGastrointestinal disorders | 2/28 | 3/29 | 3/27 |
| HeadacheNervous system disorders | 2/28 | 2/29 | 2/27 |
| Chest discomfortGeneral disorders | 0/28 | 0/29 | 2/27 |
| DizzinessNervous system disorders | 2/28 | 2/29 | 0/27 |
| Ovarian cystReproductive system and breast disorders | 2/28 | 0/29 | 0/27 |
| FatigueGeneral disorders | 2/28 | 0/29 | 1/27 |
| Upper respiratory tract infectionInfections and infestations | 0/28 | 2/29 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 2/29 | 0/27 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/28 | 2/29 | 0/27 |
Amongst the 85 randomized subjects, 84 subjects were included in the safety analysis set (1 subject in the placebo group discontinued due to protocol deviation).
| Age, Categorical(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 28 | 29 | 27 | 84 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| Mean | 32.6 ± 7.2 | 33.4 ± 6.4 | 32.1 ± 6.9 | 32.7 ± 6.8 |
| Age, Customized(years) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| Median | 32.5 (28.0 to 36.0) | 34.0 (29.0 to 37.0) | 31.0 (26.0 to 37.0) | 33.0 (28.0 to 37.0) |
| Sex: Female, Male(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| Female | 28 | 29 | 27 | 84 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 12 | 9 | 28 |
| Not Hispanic or Latino | 20 | 17 | 18 | 55 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 5 | 10 |
| White | 22 | 27 | 20 | 69 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| Canada | 1 | 2 | 0 | 3 |
| Puerto Rico | 4 | 2 | 0 | 6 |
| United States | 23 | 25 | 28 | 76 |
| Weight(kg) | LGX 75 mg | LGX 200 mg+ABT | Placebo | Total |
|---|---|---|---|---|
| Mean | 78.130 ± 16.904 | 76.540 ± 20.207 | 71.280 ± 16.050 | 75.379 ± 17.885 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 112 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Jan 2021, 19 months.
Results were first posted in Oct 2024, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linzagolix
Kissei Pharmaceutical Co., Ltd. →